Some of the more recent failures in lupus trials include anti-CD20 (rituximab), anti-CD22 (epratuzumab), anti-BAFF (tabalumab, atacicept) CD28-Fc (abatacept), anti-IL6 (PF-04236921), and anti-IFN-α (sifalimumab) [29]. Here, CD28 is linked to systemic lupus erythematosus.